Efficacy and safety of apatinib or anlotinib combined with PD-1 inhibitors-based therapy as subsequent-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a real-world retrospective study
In patients with R/M NPC that progressed after first-line therapy, the combination of anti-angiogenic agents (apatinib or anlotinib) with PD-1 inhibitors based therapy demonstrated a promising antitumor efficacy and an acceptable safety profile. These findings were consistent even among patients from non-endemic regions.
Authors
- Xia He (ORCID: https://orcid.org/0000-0002-7314-1002)
- Jingjing Gao (ORCID: https://orcid.org/0000-0003-4226-3944)
- Jingshu Xu (ORCID: https://orcid.org/0000-0002-0130-348X)
- Dan Zong (ORCID: https://orcid.org/0000-0003-4984-4557)
- Yiyue He
- Tong Jin (ORCID: https://orcid.org/0000-0003-0791-2822)
Institutions
- Xuzhou Medical College (CN)
- Jiangsu Cancer Hospital (CN)
- Second Affiliated Hospital of Nanjing Medical University (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-11-06
- DOI
- https://doi.org/10.3389/fonc.2025.1624286
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00